Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas

NCT03079999 Phase 2 ACTIVE_NOT_RECRUITING

This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

Details

Lead sponsor	Massachusetts Eye and Ear Infirmary
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	97
Start date	2018-06-11
Completion	2029-02

Conditions

• Vestibular Schwannoma
• Acoustic Neuroma
• Neurofibromatosis 2

Interventions

• Aspirin
• Placebo

Primary outcomes

• Progression Free Survival — Progression, or around 3.5 years
  Progression Free Survival (PFS) is the length of time from start of study treatment to tumor growth of more than 20%.

Countries

United States